Coronavirus company news summary – Canada permits import of J&J Covid-19 shots made at Emergent facility - Bonus BioGroup drug lowers Covid-related death by 94% in Phase II trial
Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here
X

Coronavirus company news summary – Canada permits import of J&J Covid-19 shots made at Emergent facility – Bonus BioGroup drug lowers Covid-related death by 94% in Phase II trial

25 Nov 2021

Health Canada has permitted Johnson & Johnson to import its Covid-19 vaccine made with a drug substance produced at contract manufacturer Emergent BioSolutions’ facility in Baltimore, US. The move comes after Health Canada, European Medicines Agency and South African Health Products Regulatory Authority concluded inspection at the site and found that the plant was Good Manufacturing Practices-compliant. In June this year, Health Canada had decided to not release the batches of product or ingredients made at the plant until it finished the site inspection.

Bangladesh-based company Globe Biotech is set to commence the human clinical trials of its Covid-19 vaccine, Bangavax, next month, Arab News reported. Bangavax is the first-ever Covid-19 vaccine made in the country to enter trials on obtaining approval from the Bangladesh Medical Research Council. A single-dose messenger ribonucleic acid (mRNA) vaccine, Bangavax introduces a fragment of mRNA that resembles a viral protein and induces an immune response that generates virus antibodies.

Israel based company Bonus BioGroup has reported data from a multicentre Phase III clinical trial where its drug MesenCure offered a 70% decline in mortality in severe Covid-19 patients with pneumonia and respiratory distress. Following the 30-day follow-up period, the survival rate of the 50 hospitalised subjects treated with MesenCure was found to be 94%. The treatment reduced the average time in hospital by eight days, with a relative decline of 45% as against the control arm. Furthermore, nearly half of the subjects in the MesenCure arm were discharged from the hospital up to one day after concluding the therapy.